消息面上，中国同辐发布公告称，预计年度收益约69.79亿元至72.06亿元人民币，同比减少约5%至 8%；净利润约6.11亿元至6.55亿元人，同比减少约25%至30%；权益股东应占年内利润约3.02亿元至3.22 亿元人民币，同比减少约20%至25%。 中国同辐(01763)盈警后跌超7%，截至发稿，跌6.54%，报20.3港元，成交额1147.11万港元。 公告称，截至目前，公司经营运作正常，2025年度收益减少主要由于本集团的核医疗装备分部收益下 降，利润减少主要由于本公司附属公司深圳市中核海得威生物科技有限公司补缴税费及滞纳金影响。 ...

格隆汇2月12日丨中国同辐(01763.HK)公告，根据对集团截至2025年12月31日止年度的未经审核综合管 理账目及现时可得数据之初步审阅，预期与2024年同期相比：收益预计约人民币69.79亿元至人民币 72.06亿元，同比减少约5%至8%；净利润预计约人民币6.11亿元至人民币6.55亿元，同比减少约25%至 30%；公司权益股东应占年内利润预计约人民币3.02亿元至人民币3.22亿元，同比减少约20%至25%。截 至目前，公司经营运作正常，2025年度收益减少主要由于集团的核医疗装备分部收益下降，利润减少主 要由于公司附属公司深圳市中核海得威生物科技有限公司补缴税费及滞纳金影响。 来源：格隆汇APP ...

智通财经APP讯，中国同辐(01763)发布公告，根据对本集团截至2025年12月31日止年度的未经审核综合 管理账目及现时可得数据之初步审阅，预期与2024年同期相比：收益预计约人民币69.79亿元至人民币 72.06亿元，同比减少约5%至8%;净利润预计约人民币6.11亿元至人民币6.55亿元，同比减少约25%至 30%;本公司权益股东应占年内利润预计约人民币3.02亿元至人民币3.22亿元，同比减少约20%至25%。 截至目前，公司经营运作正常，2025年度收益减少主要由于本集团的核医疗装备分部收益下降，利润减 少主要由于本公司附属公司深圳市中核海得威生物科技有限公司补缴税费及滞纳金影响。 ...

Core Viewpoint - China Tongru (01763) has been recognized for its ESG practices at the ESG China Innovation Annual Conference (2025), highlighting its commitment to health and sustainable development through nuclear technology [1] Group 1: ESG Recognition - The company received the "China ESG Excellence Practice (2025)" award from the China Enterprise Reform and Development Research Association [1] - It was also listed among the "China ESG Listed Central Enterprises Pioneer 100 (2025)" by the China Central Radio and Television [1] Group 2: Technological Innovation - The company has established a comprehensive innovation system covering radioactive drugs, nuclide preparation, and nuclear medical equipment [1] - It focuses on addressing critical technology challenges and positions itself as a guardian of public health [1] Group 3: Sustainable Development - The company promotes green development to facilitate its transformation and upgrade [1] - It has innovated a circular economy development model for nuclear technology applications, achieving a balance between economic, environmental, and social benefits [1]

Core Viewpoint - China Tongru (01763) has been recognized for its ESG practices at the ESG China Innovation Annual Conference (2025), highlighting its commitment to health and sustainable development through nuclear technology [1] Group 1: ESG Recognition - The company received the China ESG Excellence Practice (2025) award from the China Enterprise Reform and Development Research Association [1] - It was also listed among the China ESG Listed Central Enterprises Pioneer 100 (2025) by the China Central Radio and Television [1] Group 2: Innovation and Development - The company has established a comprehensive innovation system covering radioactive drugs, nuclide preparation, and nuclear medical equipment [1] - It focuses on addressing critical technology challenges and positions itself as a guardian of public health [1] Group 3: Sustainable Development - The company promotes green development to facilitate its transformation and upgrade [1] - It has innovated a circular economy development model for nuclear technology applications, achieving synergy between economic, environmental, and social benefits [1]

Core Viewpoint - China Tongru (01763.HK) has been recognized for its ESG practices at the ESG China Innovation Conference (2025), highlighting its commitment to health and sustainable development through nuclear technology [1] Group 1: ESG Recognition - The company received the "China ESG Excellence Practice (2025)" award from the China Enterprise Reform and Development Research Association [1] - It was also listed among the "China ESG Listed Central Enterprises Pioneer 100 (2025)" by the China Central Radio and Television [1] Group 2: Innovation and Development - The company has established a comprehensive innovation system covering radioactive drugs, nuclide preparation, and nuclear medical equipment [1] - It emphasizes technological innovation to address critical technology challenges and positions itself as a guardian of public health [1] Group 3: Sustainable Development - The company promotes green development to facilitate its transformation and upgrade [1] - It aims to achieve a synergistic development of economic, environmental, and social benefits through innovative applications of nuclear technology and a circular economy model [1]

Core Viewpoint - China Dongfang (01763) has been recognized for its ESG practices at the ESG China Innovation Conference 2025, highlighting its commitment to health and sustainable development through nuclear technology [1] Group 1: ESG Recognition - The company received the China ESG Excellence Practice (2025) award from the China Enterprise Reform and Development Research Association [1] - It was also listed among the China ESG Listed Central Enterprises Pioneer 100 (2025) by the China Central Radio and Television [1] Group 2: Technological Innovation - The company is building a comprehensive innovation system covering radioactive drugs, nuclide preparation, and nuclear medical equipment [1] - It is focusing on addressing critical technology challenges and positioning itself as a guardian of public health [1] Group 3: Sustainable Development - The company promotes green development to facilitate its transformation and upgrade [1] - It aims to achieve a synergistic development of economic, environmental, and social benefits through innovative applications of nuclear technology and a circular economy model [1]

Core Insights - The Sichuan government is prioritizing the development of the nuclear medicine industry, aiming to establish a world-class nuclear medicine industrial hub [3][4] - New policy measures have been introduced to address challenges in the nuclear medicine sector, focusing on regulatory efficiency, innovation, market demand, and a supportive environment [3][5][6] Regulatory Efficiency - Six measures have been proposed to enhance regulatory efficiency, including the establishment of a more scientific and effective regulatory system [3] - The government aims to streamline regulations for new treatment technologies, such as Flash radiation therapy, and support the development of relevant guidelines [3][4] Innovation Empowerment - Four measures are focused on fostering innovation in the nuclear medicine sector, including support for research on new drug targets and the establishment of integrated platforms for industry-academia-research collaboration [4] - The government encourages joint innovation among industry players to enhance the overall development of the nuclear medicine field [4] Expanding Market Demand - Seven measures aim to stimulate end-user demand, which is expected to drive growth across the entire nuclear medicine supply chain [5][6] - Initiatives include promoting the application of domestic nuclear medical equipment in hospitals and encouraging the development of commercial insurance products related to nuclear medicine [6] Supportive Environment - Seven measures are designed to create a favorable environment for the nuclear medicine industry, including the establishment of a consultation mechanism for the industry chain and the promotion of government investment funds [6][7] - The government plans to address financing challenges faced by nuclear medicine enterprises by leveraging policy financial tools and encouraging public-private partnerships [7]

Core Viewpoint - China Dongfang (01763) reported a revenue of 2.858 billion RMB for the six months ending June 30, 2025, representing a year-on-year increase of 1.69% [1] - The company's profit attributable to equity shareholders was 172 million RMB, an increase of 11.33% year-on-year, with basic earnings per share of 0.54 RMB [1] - A mid-term dividend of 0.0807 RMB per share is proposed [1] Group Focus - The company focuses on two main industry directions: nuclear medical health and irradiation applications, aiming to provide comprehensive solutions in nuclear medicine and radiation therapy [1] - The business model is structured around a "6+N" industrial layout, which includes six core businesses: radionuclides, radiopharmaceuticals, nuclear medical equipment, overall solutions for nuclear medicine, radiation sources and applications, and irradiation applications [1] Business Operations - The company is engaged in the research, development, manufacturing, and sales of radioactive pharmaceuticals for diagnosis and treatment, as well as medical and industrial radiation source products [1] - It provides services such as irradiation sterilization, material modification, and the design, manufacturing, installation engineering, procurement, and construction (EPC) services of irradiation devices [1] - Additionally, the company offers nuclear medical equipment and construction services for nuclear medicine departments to hospitals and other medical institutions [1]

Group 1 - The company reported a revenue of 2.858 billion RMB for the six months ending June 30, 2025, representing a year-on-year increase of 1.69% [1] - The profit attributable to equity shareholders was 172 million RMB, an increase of 11.33% year-on-year [1] - The basic earnings per share were 0.54 RMB, and the company proposed an interim dividend of 0.0807 RMB per share [1] Group 2 - The company focuses on two main industry directions: nuclear medical health and irradiation applications, aiming to provide comprehensive solutions in nuclear medicine and radiation therapy [1] - The business model is structured around a "6+N" industrial layout, which includes six core business areas: radionuclides, nuclear pharmaceuticals, nuclear medical equipment, overall solutions for nuclear medicine, radiation sources and applications, and irradiation applications [1] - The company is engaged in the research, development, manufacturing, and sales of radioactive pharmaceuticals for diagnosis and treatment, as well as medical and industrial radiation source products [1]